The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Vanderbilt Health Operating Margin Climbs to 4.7% in FY 2026

Vanderbilt Health improved its financial footing in fiscal 2026, reporting $452 million in operating income and a 4.7% operating margin for the 12 months ended June 30, according to its Sept. 30 financial report cited by Becker's Hospital Review. That is a sharp step up from the $255 million in operating income and 3.0% margin the Nashville-based system recorded a year earlier.

The gains came on $9.5 billion in operating revenue, signaling that top-line growth is now outrunning the cost and labor pressures that squeezed hospitals through the pandemic's aftermath. For a large academic system, a margin near 5% marks a return to the kind of financial cushion needed to fund capital projects, technology, and clinical expansion.

Vanderbilt's results track a wider recovery across big nonprofit health systems, many of which have reported stronger operating performance over the past year as volumes stabilize and expense inflation eases. The question for operators is whether these margins hold as reimbursement and policy pressures mount.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.